GAP Pharmagap Inc.

, 2011 - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the
Company") today announced that the in-life protocol for its definitive in vivo
efficacy study has been completed in accordance with the test design. In this
test, a total of 168 mice were employed, with the final group euthanized on
December 16th. The investigators will now turn to collection, measurement,
compilation and analysis of results, which are expected to become available to
the Company around the end of January.


Results from this study will provide the Company with the in vivo efficacy proof
of concept required to proceed to clinical trials in humans and with the basis
to select a final formulation and liposomal carrier with which to proceed to
large scale GMP manufacturing for use in human trials.


PharmaGap drug compounds tested in this study included GAP-107B8 in a liposomal
formulation, GAP-107B8 in a targeted liposomal formulation, and an enhanced
variant of GAP-107B8 alone and in a liposomal formulation. The study
investigated the efficacy of these compounds in models of three human ovarian
cancer cell lines established in mice. Cancer cells were introduced into the
mice by intraperitoneal injection in order to establish and grow tumours of that
cancer cell type. The Pharmagap drug compounds were administered to the mice by
intraperitoneal injection up to 5 times over a 12 day treatment period. 


One of these cell lines - OCC1 - was selected because it is known to form
primary peritoneal ascites and small tumour nodules following intraperitoneal
xenograft into immune-deficient mice. The initial in vivo screen of this cell
line was performed in June of 2011 and provided early evidence that PharmaGap's
enhanced peptides could be effective when administered via the intraperitoneal
route. The second cell line - ES-2 - has also been associated with the
production of peritoneal ascites and solid tumours. The third cell line -
A2780cp - was chosen on the basis that it is a chemotherapy-resistant cell line
associated with undifferentiated solid tumours and negligible production of
ascites. Evaluation of this cell line allows the Company to investigate the
potential therapeutic efficacy of the drug compounds and formulations in the
most challenging clinical scenario, treatment of chemo-resistant ovarian cancer.
Peritoneal ascites is a significant cause of morbidity in women with ovarian
cancer, and is also present in other forms of cancer, is associated with
increased level of metastases of many cancers, and is also present in other
gastro-intestinal disease conditions.


Following euthanization, peritoneal ascites fluid is collected (in the case of
the OCC1 and ES-2 cell lines), and the volume determined for each treatment
group. All detectable tumour tissue is retrieved, weighed, and noted for the
degree of dissemination of the tumours. Samples of tumour tissue and normal
abdominal wall tissue are retained for analysis.


Analysis of the data will generate graphs of tumour burden and of ascites
volumes in order to compare the effect of the three PharmaGap formulations, the
liposomal carrier without the PharmaGap drug compound embedded, and carboplatin,
a chemotherapy drug used in ovarian cancer treatment included as a positive
control, all relative to an untreated control group.


The Company will report on the findings of the investigators around the end of
January following receipt and complete analysis of all test data and
observations.


About PharmaGap Inc.

PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a biotechnology
company with a core focus on developing novel peptide therapeutics for the
treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug that has been
shown to be effective in numerous cancer types, including chemo-resistant
cancers, in vitro. For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.


Forward Looking Statements

This news release contains certain statements that constitute forward-looking
statements as they relate to the Company and its management. Forward-looking
statements are not historical facts but represent management's current
expectations of future events, and can be identified by words such as "believe",
"expects", "will", "intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes that
expectations represented in such forward-looking statements are reasonable,
there can be no assurance that they will prove to be correct.


By their nature, forward-looking statements include assumptions and are subject
to inherent risks and uncertainties that could cause actual future results,
conditions, actions or events to differ materially from those in the
forward-looking statements. If and when forward-looking statements are set out
in this news release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except as expressly
required by applicable securities laws, the Company assumes no obligation to
update or revise any forward-looking statements. The future outcomes that relate
to forward-looking statements may be influenced by many factors, including, but
not limited to: results of ongoing product testing and development; regulatory
approvals required to complete development of products; ability to manufacture
product at quality and scale for human use on an economically sound basis;
patient reimbursement by private and public health insurance programs;
unintended side effects of products; competitive products; product liability;
intellectual property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of financing;
distribution of securities; effect of market interest rates on price of
securities, and potential dilution.


Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. No Securities
Commission or other regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This release
contains forward looking statements that may not occur or may change materially.

Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From May 2024 to Jun 2024

Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jun 2023 to Jun 2024